Read by QxMD icon Read

Journal of Medical Economics

Emi Watanabe-Fujinuma, Benjamin F Banderas, Yukihiro Koretsune, Koichiro Kumagai, Shinichiro Uchiyama, Takeshi Yamashita, Masahiro Yasaka, Sayako Akiyama, Jean-Baptiste Briere, Gavin Dickie, Stefan J Cano
AIMS: The Anti-Clot Treatment Scale (ACTS) and Treatment Satisfaction Questionnaire for Medication version II (TSQM-II) are validated treatment satisfaction patient-reported outcome (PRO) instruments. The ACTS includes two domains: Burdens and Benefits; the TSQM-II includes four: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Japanese-language versions of the ACTS and TSQM-II have been developed and linguistically validated. This study aimed to assess their psychometric properties in Japanese patients with atrial fibrillation (AF)...
April 17, 2019: Journal of Medical Economics
Regina Grebla, Juliana Setyawan, Chanhyun Park, Kristin M Richards, Esmond D Nwokeji, Manjiri Pawaskar, M Haim Erder, Kenneth A Lawson
OBJECTIVES: To examine suboptimal response (SR) in attention deficit hyperactivity disorder (ADHD) among pediatric patients in the Texas Medicaid program receiving osmotic-release oral system methylphenidate (OROS-MPH) or lisdexamfetamine (LDX) and apply an SR prediction model to identify patients most likely to experience an SR to either OROS-MPH or LDX therapies. METHODS: A retrospective cohort study was conducted using Texas Medicaid claims data of ADHD children and adolescents (6 to 17 years of age) initiating OROS-MPH or LDX...
April 15, 2019: Journal of Medical Economics
Der-Yuan Chen, Ping-Ning Hsu, Chao-Hsiun Tang, Lindsay Claxton, Satish Valluri, Robert A Gerber
AIMS: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis investigated the cost-effectiveness of the second-line treatment with tofacitinib, compared with adalimumab, both plus methotrexate (MTX), in patients with moderate to severe RA and an inadequate response to the first-line MTX, from a Taiwan National Health Insurance Administration perspective. MATERIALS AND METHODS: A patient-level simulation model was used to project lifetime costs and quality-adjusted life-years (QALYs)...
April 13, 2019: Journal of Medical Economics
Janet H Ford, Wenyu Ye, Russell M Nichols, Shonda A Foster, David R Nelson
AIM: Within a treated migraine population, to evaluate if the subgroup meeting criteria for high disease-specific total costs is significantly different than the subgroup with medium and/or low-costs, and to identify the associated risk factors. METHODS: Data from the Household Component of Medical Expenditure Panel Survey (MEPS-HC, 2008-2012), a nationally representative survey of noninstitutionalized civilians in USA, were analyzed. Key inclusion criteria were migraine diagnosis (ICD-9 code: 346...
April 12, 2019: Journal of Medical Economics
Jean-Baptiste Briere, Kevin Bowrin, Aurélie Millier, Mondher Toumi, Piotr Wojciechowski, Vanessa Taieb
AIMS: Non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) are used to prevent stroke in patients with atrial fibrillation (AF). This paper aimed to evaluate the clinical efficacy and safety of NOACs when compared to VKAs by calculating the number needed to treat (NNT) at 2 years using incidence rates and hazard ratios (HRs) derived from a meta-analysis of studies conducted in real-world settings. MATERIALS AND METHODS: HRs were sourced from a published systematic literature review and a meta-analysis of real-world evidence on the use of NOACs versus VKAs...
April 10, 2019: Journal of Medical Economics
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy, Wolfgang Willenbacher
AIM: The approved indication for denosumab (120 mg) was expanded in 2018 to include skeletal-related event (SRE) prevention in patients with multiple myeloma (MM). Therefore, we conducted a cost-effectiveness analysis comparing denosumab with zoledronic acid (ZA) for SRE prevention in patients with MM from the national healthcare system perspective in a representative sample of European countries: Austria, Belgium, Greece, and Italy. METHODS: The XGEVA global economic model for patients with MM was used to calculate incremental cost-effectiveness ratios (ICERs) for denosumab versus ZA over a lifetime horizon...
April 10, 2019: Journal of Medical Economics
Shaoyan Hu, Yi Han, Wenjie Zhang, Tianxiang Zhang, Xingxing Yao, Li Liu
AIMS: To conduct a lifetime cost-effectiveness analysis (CEA) of rasburicase compared with standard of care (SOC) for tumor lysis syndrome (TLS) in children with hematologic malignancies from the Chinese healthcare system perspective. MATERIALS AND METHODS: The CEA was performed using a decision tree model with a lifetime horizon. The model explores the cost-effectiveness of rasburicase verses SOC for both preventing TLS and treating established TLS among pediatric patients with acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and non-Hodgkin's lymphoma (NHL)...
April 3, 2019: Journal of Medical Economics
Heather M Rozjabek, Craig I Coleman, Veronica Ashton, Francois Laliberte, Paul Oyefesobi, Dominique Lejeune, Guillaume Germain, Jeff R Schein, Zhong Yuan, Patrick Lefebvre, Eric D Peterson
OBJECTIVE: To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs). MATERIAL AND METHODS: Optum's Clinformatics Data Mart database from 1/2009-12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores...
April 3, 2019: Journal of Medical Economics
Marianne Chacón-Araya, Diego Rey-Rodríguez, Felipe Rodríguez De León, Allan Ramos-Esquivel, Tao Sunning
OBJECTIVES: There is a lack of data in Panama on the potential differences in total health care professional (HCP) time between routine administrations of short-acting erythropoietin simulating agents (ESAs) (i.e., epoetin alfa) and continuous erythropoietin receptor activator (CERA) (i.e., methoxy polyethylene glycol-epoetin beta). We aimed to quantify the HCP time associated with a single administration of epoetin alfa and CERA for the treatment of anemic patients with chronic kidney disease (CKD) on hemodialysis...
March 27, 2019: Journal of Medical Economics
Zhaoxin Qian, Yinhuai Wang, Zhengyan Tang, Da Ren, Zhao Wang, Wendong Chen, Zhihong Li
OBJECTIVES: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients. METHODS: This retrospective study identified a group of patients with newly developed mCRPC from 2012 to 2016 to extract information from their medical and billing records in two tertiary care hospitals. Descriptive statistical methods were used to summarize patient clinical characteristics, treatment pattern, and monthly medical costs...
March 27, 2019: Journal of Medical Economics
Mihajlo Jakovljevic, Melitta Jakab, Ulf Gerdtham, David McDaid, Seiritsu Ogura, Elena Varavikova, Joav Merrick, Roza Adany, Albert Okunade, Thomas Getzen
The pandemic of chronic noncommunicable diseases (NCDs) poses substantial challenges to the health financing sustainability in high-income and low/middle income countries (LMICs). The aim of this review is to identify the bottle neck inefficiencies in NCDs attributable spending and propose sustainable health financing solutions. The World Health Organization (WHO) introduced the "best buy" concept to scale up the core intervention package against NCDs targeted for LMICs. Population- and individual- based NCD best buy interventions are projected at US$170 billion over 2011-2025...
March 27, 2019: Journal of Medical Economics
Xiaocang Xu, Linhong Chen
BACKGROUND: More and more disabled elderly need long-term care as China becomes an aging society. In 2016, there were 220 million people over the age of 60 and nearly 10 million completely disabled elderly people who cannot complete Activities of Daily Living (ADLs). Therefore, the topic of influencing factors for disability among the elderly in China has attracted close attention from researchers, most of which use the traditional empirical methods, such as Ordinary Least Squares (OLS) and logistic...
March 26, 2019: Journal of Medical Economics
Abhishek S Chitnis, Mollie Vanderkarr, Jill Ruppenkamp, Jason Lerner, Chantal E Holy, Charisse Sparks
OBJECTIVE: This study evaluated the frequency of reoperation within one year of initial intramedullary fixation for patients with pertrochanteric hip fracture and compared one-year healthcare resource utilization and cost burden for patients with and without reoperation. METHODS: This is a retrospective evaluation of medical claims from the United States Centers for Medicare and Medicaid Standard Analytic File. Patients aged ≥65 years who underwent fixation with an intramedullary implant for a pertrochanteric fracture between 2013-2015 were included...
March 26, 2019: Journal of Medical Economics
Antoine Lafuma, François-Emery Cotté, Christophe Le Tourneau, Corinne Emery, Anne-Françoise Gaudin, Elodie Torreton, Julie Gourmelen, Julia Bonastre
AIMS: Overall survival (OS) of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is extremely poor. New therapeutic options emerge but need to establish their economic value. The objective was to describe the direct and related costs of R/M SCCHN in France. MATERIALS AND METHODS: We selected all adult patients treated with chemotherapy for R/M SCCHN between 1 January 2009 and 31 December 2014 from the permanent sample of the French national health insurance database (EGB)...
March 21, 2019: Journal of Medical Economics
Linda Harris, Sophie Graham, Sharon MacLachlan, Alex Exuzides, Saiju Jacob
AIMS: To examine healthcare resource utilization associated with refractory myasthenia gravis (MG) in England. MATERIALS AND METHODS: This was a retrospective cohort study of linked data from the Clinical Practice Research Datalink and the Hospital Episode Statistics database collected between 1997 and 2016. Included patients were ≥18 years of age at the index MG diagnosis. Patients with refractory MG were identified using an algorithm based on treatments received...
March 7, 2019: Journal of Medical Economics
Chung-Ping A Loh, Kristopher P Croome, C Burcin Taner, Andrew P Keaveny
INTRODUCTION: Fast-tracking is an approach adopted by Mayo Clinic in Florida's (MCF) liver transplant (LT) program which consists of early tracheal extubation and transfer of patients to surgical ward eliminating a stay in the intensive care unit in select patients. Since adopting this approach in 2002, MCF has successfully fast-tracked 54.3% of patients undergoing LT. OBJECTIVES: This study evaluated the reduction in post-operative length of stay (LOS) that resulted from the fast-tracking protocol and assessed the potential cost saving in the case of nationwide implementation...
March 6, 2019: Journal of Medical Economics
Samer A Kharroubi, Yara Beyh
Preference-based measures of health-related quality of life including, but not limited to, the EQ-5D, HUI2 and the SF-6D have been increasingly used in calculations of quality-adjusted life years for cost effectiveness analyses. However, the uncertainty around the measures' value sets is commonly ignored in economic evaluation. There are several types of uncertainties including methodological, structural, and parameter uncertainties, with the latter being the focus of this review paper. Our objective is to highlight the gap in the literature regarding the existence of uncertainty in the value sets, focusing mainly on the EQ-5D and SF-6D...
March 6, 2019: Journal of Medical Economics
Katelyn Keyloun, Eric Lofgren, Scott Hebert
AIMS: To model implementation of a new treatment pathway leveraging long-acting antibiotics (LAs) for treatment of acute bacterial skin and skin structure infections (ABSSSIs) in a hospital emergency department (ED) with an observation unit, and to quantify health resource utilization and economic outcomes versus standard care (intravenous vancomycin). MATERIALS AND METHODS: Discrete-event simulation was used to model implementation of the LA treatment pathway in the ED versus standard care from the US Medicare perspective...
March 6, 2019: Journal of Medical Economics
Eric L Keuffel, John Rizzo, Mitali Stevens, Candace Gunnarsson, Kamal Maheshwari
OBJECTIVE: Recent studies indicate intraoperative hypotension, common in non-cardiac surgical patients, is associated with myocardial injury, acute kidney injury and mortality. This study extends on these findings by quantifying the association between intraoperative hypotension and hospital expenditures in the United States. METHODS: Monte Carlo simulations (10,000 trial per simulation) based on current epidemiological and cost outcomes literature were developed for both acute kidney injury (AKI) and myocardial injury in non-cardiac surgery (MINS)...
March 6, 2019: Journal of Medical Economics
Abdalla Aly, Courtney Johnson, Shuo Yang, Marc F Botteman, Sumati Rao, Arif Hussain
AIMS: Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT) but invariably progress, requiring additional LOTs and healthcare resource use (HCRU). To better understand the evolving mUC treatment landscape, we estimated the economic burden of chemotherapy-based mUC treatments among US Medicare patients. METHODS: Newly diagnosed Medicare patients with mUC were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database...
March 6, 2019: Journal of Medical Economics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"